About Intercept Pharmaceuticals
Intercept Pharmaceuticals is a company based in New York (United States) founded in 2002 by Mark Pruzanski was acquired by Alfasigma in September 2023.. Intercept Pharmaceuticals has raised $121 million across 5 funding rounds from investors including Orbimed, Alfasigma and Genextra. The company has 341 employees as of December 31, 2022. Intercept Pharmaceuticals offers products and services including FXR Agonist. Intercept Pharmaceuticals operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter New York, United States
- Employees 341 as on 31 Dec, 2022
- Founders Mark Pruzanski
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Intercept Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Intercept Pharmaceuticals
Intercept Pharmaceuticals offers a comprehensive portfolio of products and services, including FXR Agonist. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for primary biliary cholangitis liver disease
Unlock access to complete
Unlock access to complete
Leadership Team
61 people
Software Development Team
47 people
Operations Team
16 people
Product Management Team
9 people
Human Resources and Administration
5 people
Legal and Compliance
4 people
Head Team
4 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Intercept Pharmaceuticals
Intercept Pharmaceuticals has successfully raised a total of $121M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $500.0M
-
First Round
First Round
(16 May 2006)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2021 | Amount | Post-IPO - Intercept Pharmaceuticals | Valuation |
investors |
|
| Sep, 2012 | Amount | Series C - Intercept Pharmaceuticals | Valuation | Orbimed | |
| Jan, 2010 | Amount | Series B - Intercept Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Intercept Pharmaceuticals
Intercept Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Alfasigma and Genextra. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
A holding company focused on life science investments is operated.
|
Founded Year | Domain | Location | |
|
Manages investments and risks to deliver consistent returns for institutional investors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Intercept Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Intercept Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Intercept Pharmaceuticals Comparisons
Competitors of Intercept Pharmaceuticals
Intercept Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for metabolic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for liver disease and cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Intercept Pharmaceuticals
Frequently Asked Questions about Intercept Pharmaceuticals
When was Intercept Pharmaceuticals founded?
Intercept Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Where is Intercept Pharmaceuticals located?
Intercept Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Intercept Pharmaceuticals a funded company?
Intercept Pharmaceuticals is a funded company, having raised a total of $121M across 5 funding rounds to date. The company's 1st funding round was a Series B of $25M, raised on May 16, 2006.
How many employees does Intercept Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Intercept Pharmaceuticals is 341.
What is the annual revenue of Intercept Pharmaceuticals?
Annual revenue of Intercept Pharmaceuticals is $285.71M as on Dec 31, 2022.
What does Intercept Pharmaceuticals do?
Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.
Who are the top competitors of Intercept Pharmaceuticals?
Intercept Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does Intercept Pharmaceuticals offer?
Intercept Pharmaceuticals offers FXR Agonist.
Who are Intercept Pharmaceuticals's investors?
Intercept Pharmaceuticals has 5 investors. Key investors include Orbimed, Alfasigma, Genextra, Balyasny Asset Management, and JAFCO Group.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.